MediGene AG (MDGEF)

0.10 0.00 (0.00%) USD  |  OTCM  |  Sep 04, 16:00
More

MediGene Research and Development Expense (Quarterly)

Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for MDGEF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2007. Start Trial.
Date Value
December 31, 2019 6.819M
September 30, 2019 6.160M
June 30, 2019 6.052M
March 31, 2019 6.286M
December 31, 2018 4.386M
September 30, 2018 5.354M
June 30, 2018 5.183M
March 31, 2018 5.308M
December 31, 2017 4.479M
September 30, 2017 4.270M
June 30, 2017 4.208M
March 31, 2017 3.850M
December 31, 2016 3.831M
September 30, 2016 3.243M
June 30, 2016 3.031M
March 31, 2016 2.640M
December 31, 2015 2.534M
September 30, 2015 2.331M
June 30, 2015 2.416M
March 31, 2015 2.172M
December 31, 2014 2.642M
September 30, 2014 2.618M
June 30, 2014 2.484M
March 31, 2014 2.187M
December 31, 2013 2.023M
Date Value
September 30, 2013 2.215M
June 30, 2013 2.210M
March 31, 2013 2.314M
December 31, 2012 2.892M
September 30, 2012 1.917M
June 30, 2012 2.304M
March 31, 2012 2.412M
December 31, 2011 8.132M
September 30, 2011 2.320M
June 30, 2011 2.224M
March 31, 2011 2.776M
September 30, 2010 4.732M
June 30, 2010 4.354M
March 31, 2010 5.638M
December 31, 2009 6.212M
September 30, 2009 6.874M
June 30, 2009 6.426M
March 31, 2009 5.245M
December 31, 2008 6.458M
September 30, 2008 9.853M
June 30, 2008 12.55M
March 31, 2008 9.936M
December 31, 2007 9.820M
September 30, 2007 9.707M
June 30, 2007 9.434M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
InflaRx NV 5.510M
BioNTech SE 514.38M
Immatics NV 72.57M
Arrowhead Pharmaceuticals, Inc. 192.06M
Oncolytics Biotech, Inc. 4.262M